Clinilabs

Schizophrenia is a chronic mental illness that, if left untreated, can be severe and disabling. Worldwide, approximately 24 million people live with schizophrenia, with 3.7 million of those individuals residing in the United States. For over 60 years, the dopaminergic hypothesis of schizophrenia has formed the basis of the schizophrenia treatment paradigm, as both the first and second-generation antipsychotics target primarily dopamine and other monoamines. Last week, Karuna/Bristol Myers Squibb received approval for KarXT (COBENFY™), the first new drug class for schizophrenia with a unique mechanism of action approved in decades. This approval was based on two pivotal phase III trials where patients experiencing acute psychotic episodes who took KarXT twice daily for five weeks experienced an average reduction of about 21 points on the Positive and Negative Syndrome Scale (PANSS) score, which measures the severity of schizophrenia on a scale from 30 to 210. In comparison, patients who received a placebo in both trials saw an average reduction of around 12 points in their PANSS score. This marks a significant milestone for individuals with schizophrenia and the start of a new era in medications to combat this illness. Congratulations Karuna/Bristol Myers Squibb for this achievement. To read the full article visit: https://loom.ly/6nVhuYA. #Clinilabs #Schizophrenia #MentalIllness

#ADHD diagnoses in the US increased by a million from 2016 to 2022, with 7.1 million children and adolescents diagnosed in 2022. This rise is attributed to data collected during the pandemic, which showed increased stress, depression, and anxiety in children. Girls tend to show ADHD symptoms through inattentiveness, while boys typically exhibit hyperactivity. #Clinilabs has been collaborating with the healthcare industry to find new and better treatments for ADHD. To read the complete study visit: https://loom.ly/gKTUNUg To find out how you can work with us on your next project visit: https://loom.ly/OStIpj8

As someone who has a family member with Parkinson's, this is the most incredible news ever. I look forward to the day this testing is part of a normal annual physical. Thank you #michaeljfoxfoundation for all your efforts in combatting this disease... without you we would still be nowhere. #EndParkinson #ParkinsonsDisease #Clinilabs #ClinicalResearch #ClinicalStudies

The Michael J. Fox Foundation for Parkinson’s Research announced an amazing discovery in 2023 that scientists can now detect a biomarker for Parkinson’s in a person’s spinal fluid decades before symptoms appear. This groundbreaking discovery can help diagnose people who are predisposed to have Parkinson’s disease. Early diagnosis and interventions are crucial for combating this disease. Detecting the disease early means that people with the biomarker can participate in clinical trials sooner. Organizations like #Clinlabs will be able to run clinical studies to test the effectiveness of new treatments, offering hope for better options in the future. This discovery is a significant step forward in clinical research and the development of improved treatment options for #Parkinson’s disease. For more information about 'What a biomarker is' watch this fun and informative video from MichaelJFox.Org https://loom.ly/RyEQQ7U.

We had an incredible day today at the American Medical Device Summit. If you happen to be in the area tomorrow, make sure to visit Booth #21 to discover our unparalleled expertise in medical devices and find out how we can take your project to the next level. #AMDS2024 #Clinilabs #MedicalDevice #CRO

#Clinilabs is proud to announce Lucas Abiyere as our October #EmployeeSpotlight. Lucas has been vital to the Clinilabs Global Clinical Operations team for two years. His thoughtful approach to addressing sponsors' needs is reflected in his study design, meticulous planning, and strategic implementation, enabling the successful conduct of global and decentralized clinical trials to fulfill our sponsors' requirements. Thank you, Lucas, for being an inspiration for clinical excellence.

We're here and looking forward to meeting you at the 11th annual American Medical Device Summit. Stop by Booth# 21 and find out what we're all about. #Clinilabs #MedDeviceUS24 #GenerisAMD

We make it easy for you! Find out how we can take your project to the next level. Visit https://loom.ly/y9U_T-8. #Clinilabs

With over two decades of experience, #Clinilabs has been the avenue for streamlined research managed through our proprietary processes. Find out how we can be your research partner today. Stop by Booth #21 or schedule a meeting at https://loom.ly/-ehe8w8. #MedDeviceUS24 #GenerisAMD

Narcolepsy affects an estimated 200,000 Americans and approximately 3 million people worldwide. If you're searching for the best clinical partner to conduct your next narcolepsy trial, consider contacting #Clinilabs. With over 400 sleep-related clinical trials in our portfolio, medical industry leaders trust us. To learn more about how you can collaborate with us on your next narcolepsy trial, please contact us at https://loom.ly/2Z5tmdo. #WorldNarcolepsyDay